Date:	3/8/2021	
Your Na	ame: <u>Shu</u>	incana 2hu
Manuso	cript Title:	Prognostic value of surgical intervention in advanced lung adenocarcinoma: a population-based
<u>study</u>		
	cript numbe	r (if known): JTD-21-997
	•	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial the National Natural	
1	manuscript (e.g., funding,	Science Foundation of	
	provision of study materials,	China [grant number	
	medical writing, article	81972172]	
	processing charges, etc.)	the Clinical Research Plan	
	No time limit for this item.	of Shanghai Hospital	
		Development Center	
		[grant number	
		SHDC2020CR2020B,	
		SHDC12018122]	
		the Emerging Frontier	
		Technology Project of Shanghai Shenkang	
		Hospital Development	
		Center (grant number	
		SHDC12019130).	
		Shanghai Science and	
		Technology Committee	

r			
		[grant number 19XD1423200]	
		Programs of Shanghai	
		Pulmonary Hospital [grant	
		number FKCX1904,	
		FKLY20004]	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
F	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date:	3/8/202	1
Your Na	ame: 🗇 🛛	o Ge
Manus	cript Title:	Prognostic value of surgical intervention in advanced lung adenocarcinoma: a population-based
<u>study</u>		
Manus	cript numb	er (if known):JTD-21-997
	-	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	the National Natural Science Foundation of China [grant number 81972172] the Clinical Research Plan of Shanghai Hospital Development Center [grant number SHDC2020CR2020B, SHDC12018122] the Emerging Frontier Technology Project of Shanghai Shenkang Hospital Development Center (grant number SHDC12019130). Shanghai Science and Technology Committee	

r			
		[grant number 19XD1423200]	
		Programs of Shanghai	
		Pulmonary Hospital [grant	
		number FKCX1904,	
		FKLY20004]	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
F	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date:	3/8/2021	
Your Na	ame: <u>Junijie</u>	Ημ
		Prognostic value of surgical intervention in advanced lung adenocarcinoma: a population-based
<u>study</u>		
Manuso	cript numbe	r (if known):JTD-21-997

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial the National Natural	
1	manuscript (e.g., funding,	Science Foundation of	
	provision of study materials,	China [grant number	
	medical writing, article	81972172]	
	processing charges, etc.)	the Clinical Research Plan	
	No time limit for this item.	of Shanghai Hospital	
		Development Center	
		[grant number	
		SHDC2020CR2020B,	
		SHDC12018122]	
		the Emerging Frontier	
		Technology Project of Shanghai Shenkang	
		Hospital Development	
		Center (grant number	
		SHDC12019130).	
		Shanghai Science and	
		Technology Committee	

r			
		[grant number 19XD1423200]	
		Programs of Shanghai	
		Pulmonary Hospital [grant	
		number FKCX1904,	
		FKLY20004]	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
F	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date:	3/8/2021	
Your Na	me: <u>Geni</u>	Jrong,
		Prognostic value of surgical intervention in advanced lung adenocarcinoma: a population-based
<u>study</u>		
Manusci	ript numb	er (if known):JTD-21-997
	-	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present	Time frame: Since the initial the National Natural	
1	manuscript (e.g., funding,	Science Foundation of	
	provision of study materials,	China [grant number	
	medical writing, article	81972172]	
	processing charges, etc.)	the Clinical Research Plan	
	No time limit for this item.	of Shanghai Hospital	
		Development Center	
		[grant number	
		SHDC2020CR2020B,	
		SHDC12018122]	
		the Emerging Frontier	
		Technology Project of Shanghai Shenkang	
		Hospital Development	
		Center (grant number	
		SHDC12019130).	
		Shanghai Science and	
		Technology Committee	

r			
		[grant number 19XD1423200]	
		Programs of Shanghai	
		Pulmonary Hospital [grant	
		number FKCX1904,	
		FKLY20004]	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting fees	None	
F	Doumont or honoraria for	None	
5	Payment or honoraria for lectures, presentations,	None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
9	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
10	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date:	<u>3/8/202</u> 2					
Your Na	me: <u>P.en</u>	y 2 hang				
Manusc	ript Title: <u>′</u>	Prognostic value of surgical intervention in advanced lung adenocarcinoma: a population-based				
<u>study</u>						
Manuscript number (if known):JTD-21-997						

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
Time frame: Since the initial planning of the work   1 All support for the present					
1	All support for the present manuscript (e.g., funding,	Science Foundation of			
	provision of study materials,	China [grant number			
	medical writing, article	81972172]			
	processing charges, etc.)	the Clinical Research Plan			
	No time limit for this item.	of Shanghai Hospital			
		Development Center			
		[grant number			
		SHDC2020CR2020B,			
		SHDC12018122]			
		the Emerging Frontier			
		Technology Project of Shanghai Shenkang			
		Hospital Development			
		Center (grant number			
		SHDC12019130).			
		Shanghai Science and			
		Technology Committee			

r			
		[grant number 19XD1423200]	
		Programs of Shanghai	
		Pulmonary Hospital [grant	
		number FKCX1904,	
		FKLY20004]	
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	
4	Consulting for a	News	
4	Consulting fees	None	
5	Payment or honoraria for	None	
Ū	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
0	Deutisia stieve en e Dete	News	
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	-	None	
10	Leadership or fiduciary role in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement: